These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8518427)

  • 21. Effect of Helicobacter pylori lipopolysaccharide on the synthesis of sulfated gastric mucin.
    Slomiany BL; Liau YH; Lopez RA; Piotrowski J; Czajkowski A; Slomiany A
    Biochem Int; 1992 Aug; 27(4):687-97. PubMed ID: 1417902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
    Slomiany BL; Lopez RA; Slomiany A
    Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches.
    Lindén SK; Wickström C; Lindell G; Gilshenan K; Carlstedt I
    Helicobacter; 2008 Apr; 13(2):81-93. PubMed ID: 18321298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assay of human gastric mucin as a natural antibiotic against Helicobacter pylori.
    Fukuda M; Kawakubo M; Ito Y; Kobayashi M; Lee H; Nakayama J
    Methods Enzymol; 2006; 415():164-79. PubMed ID: 17116474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipopolysaccharide a virulence factor of Helicobacter pylori: effect of antiulcer agents.
    Piotrowski J
    J Physiol Pharmacol; 1998 Mar; 49(1):3-24. PubMed ID: 9594407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of sulfation in the processing of gastric mucins.
    Liau YH; Murty VL; Slomiany A; Bielanski W; Slomiany BL
    J Physiol Pharmacol; 1991 Dec; 42(4):357-66. PubMed ID: 1726711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease.
    Sarosiek J; Bilski J; Murty VL; Slomiany A; Slomiany BL
    Am J Gastroenterol; 1989 May; 84(5):506-10. PubMed ID: 2470250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of endothelin-1 in gastric mucosal inflammatory responses to Helicobacter pylori Lipopolysaccharide: effect of omeprazole and sucralfate.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 2000 Jun; 51(2):179-92. PubMed ID: 10898092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lafutidine inhibits Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells.
    Nozawa Y; Nishihara K; Akizawa Y; Orimoto N; Nakano M; Uji T; Ajioka H; Kanda A; Matsuura N; Kiniwa M
    J Gastroenterol Hepatol; 2004 May; 19(5):506-11. PubMed ID: 15086593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Helicobacter pylori Infection on gastric mucin expression.
    Kang HM; Kim N; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Lee HS; Jung HC; Song IS
    J Clin Gastroenterol; 2008 Jan; 42(1):29-35. PubMed ID: 18097286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Helicobacter pylori urease activity by ebrotidine.
    Piotrowski J; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of Helicobacter pylori protease activity towards growth factors by sulglycotide.
    Piotrowski J; Slomiany A; Slomiany BL
    J Physiol Pharmacol; 1997 Sep; 48(3):345-51. PubMed ID: 9376617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strain- and blood group-dependent binding of Helicobacter pylori to human gastric MUC5AC glycoforms.
    Lindén S; Nordman H; Hedenbro J; Hurtig M; Borén T; Carlstedt I
    Gastroenterology; 2002 Dec; 123(6):1923-30. PubMed ID: 12454849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.
    Slomiany BL; Piotrowski J; Mojtahed H; Slomiany A
    Gen Pharmacol; 1992 Mar; 23(2):203-6. PubMed ID: 1639232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection by nitecapone against sodium taurocholate-induced damage to cultured gastric cells.
    Tu Y; Ranta S; Nissinen E; Lindén IB
    Dig Dis Sci; 1993 Apr; 38(4):701-7. PubMed ID: 7681749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of simulated gastric environments on the anti-Helicobacter activity of garlic oil.
    O'Gara EA; Maslin DJ; Nevill AM; Hill DJ
    J Appl Microbiol; 2008 May; 104(5):1324-31. PubMed ID: 18028365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of Helicobacter pylori infection on mucin expression in gastric carcinoma and pericancerous tissues.
    Wang RQ; Fang DC
    J Gastroenterol Hepatol; 2006 Feb; 21(2):425-31. PubMed ID: 16509869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hancornia speciosa: indications of gastroprotective, healing and anti-Helicobacter pylori actions.
    Moraes Tde M; Rodrigues CM; Kushima H; Bauab TM; Villegas W; Pellizzon CH; Brito AR; Hiruma-Lima CA
    J Ethnopharmacol; 2008 Nov; 120(2):161-8. PubMed ID: 18761076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.